When to stop immunotherapy for advanced melanoma: the emulated target trialsResearch in context

When to stop immunotherapy for advanced melanoma: the emulated target trialsResearch in context

Summary: Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years. Prolonged fol...

Full description

Bibliographic Details
Main Authors: Mathilde Amiot, Laurent Mortier, Stéphane Dalle, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Eve Maubec, Jean-Philippe Arnault, Florence Brunet-Possenti, Julie De Quatrebarbes, Florence Granel-Brocard, Caroline Gaudy-Marqueste, Cecile Pages, Pierre-Emmanuel Stoebner, Philippe Saiag, Thierry Lesimple, Alain Dupuy, Delphine Legoupil, Henri Montaudié, Bastien Oriano, Celeste Lebbe, Raphael Porcher
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:EClinicalMedicine
Subjects:
Advanced melanoma
Duration of treatment
Immunotherapy
Emulated trial
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702400539X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702400539X

Similar Items